Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20504580 | 0.80 | TGFBR1 (0.35) | TGFBR1 | |
| SCHEMBL13644231 | 0.76 | LMNA (0.39) | TGFBR1 | |
| SCHEMBL20504502 | 0.74 | TYK2 (0.45) | TYK2 | |
| SCHEMBL3313865 | 0.74 | PDE1B (0.37) | TGFBR1 | |
| SCHEMBL13644230 | 0.72 | LMNA (0.39) | TGFBR1 | |
| SCHEMBL20504497 | 0.71 | TYK2 (0.39) | TYK2 | |
| SCHEMBL15409256 | 0.71 | LMNA (0.39) | TGFBR1 | |
| SCHEMBL2359107 | 0.70 | CNR1 (0.36) | TGFBR1 | |
| SCHEMBL15409446 | 0.70 | APLNR (0.34) | TGFBR1 | |
| SCHEMBL2359901 | 0.70 | EGFR (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3377496-B1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2020-09-16 | — | — | EP | disclosed |
| EP-3377496-B1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2020-09-16 | — | — | EP | disclosed |
| US-10479793-B2 | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-11-19 | — | — | US | disclosed |
| US-20180325899-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2018-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10479793-B2 | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | TYK2, IL2, JAK3 | TYK2 1/4885TGFBR1 427/4885ABCB1 3051/4885 |
| US-20180325899-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | TYK2, IL2, JAK3 | TYK2 1/4885TGFBR1 427/4885ABCB1 3051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.